Abcellera Biologics is trading at $11.74, gaining +10.70% amid biotech-sector strength and continued optimism following recent Moderna-Merck trial news.
- It is outperforming the Nasdaq Composite’s +0.76% gain and the broader market.
- Biotech is up +2.06%.
- The company’s news page lists no August 25 announcement; its latest major catalyst was positive ABCL635 Phase 2 results released August 10.